An innovative portfolio that utilizes the regenerative power of hyaluronic acid.
Nearly all effects of hyaluronan observed in vitro and in vivo systems depend on its molecular weight and its concentration.
Fidia’s approach in developing the Hyal-System Line lies in the Weight – Concentration – Technology (WCT) Concept, that is the unique combination of these three variables exploit different structural and biological properties of HA, enabling each Hyal-System Line product to bring out different targeted benefits.
Nearly all effects of hyaluronan observed in vitro and in vivo systems depend on its molecular weight and its concentration.
Fidia’s approach in developing the Hyal-System Line lies in the Weight – Concentration – Technology (WCT) Concept, that is the unique combination of these three variables exploit different structural and biological properties of HA, enabling each Hyal-System Line product to bring out different targeted benefits.
February 1-3, 2024 | Palais des Congrès, Paris
Join us this January for this extraordinary 25th edition of IMCAS World Congress, and begin the new year among the best educators and innovators in medical aesthetics!
Visit Fidia booth N. Q208 | Level 2
Join our symposium on FEBRUARY 3RD | 2-3.30 PM | ROOM 351 –LEVEL 3
March 27-29, 2024 | Grimaldi Forum, Monte-Carlo
© Fidia Farmaceutici S.p.A.
Via Ponte della Fabbrica 3/A – 35031 Abano Terme (PD) – Italy
Tel. (+39) 049 8232222 Fax (+39) 049 810653
Cap. Soc. € 36.120.000 int. vers. – C.C.I.A.A. PD n. 80793 – Iscr. Reg. Imp. PD
Cod. Fisc. e P. IVA 00204260285
OUR KNOW-HOW
Powered by Ideandum
To access this page, please click YES if you are a healthcare professional.
If you are not a healthcare professional, select NO to exit.
Hydrator
Biostimulator
Dual Injectable
Lip Filler
Volumizing Filler